PharmiWeb.com - Global Pharma News & Resources
23-Jan-2019

OncoSec to Host 2019 Business Outlook Conference Call on February 1, 2019

SAN DIEGO and PENNINGTON, N.J., Jan. 22, 2019 /PRNewswire/ -- OncoSec Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing intratumoral cancer immunotherapies, today announced that it will host a 2019 Business Outlook Conference Call and audio webcast on Friday, February 1, 2019 at 9:00 a.m. ET. The Company will provide a clinical update from its KEYNOTE-695 study, an overview of its recently announced collaboration registrational-enabled cervical cancer study with the Gynecologic Oncology Group (GOG) Foundation, as well as a review of key value generating milestones the Company expects to achieve in 2019.

To access the live conference call, please dial (844) 562-3893 (domestic) or (409) 220-9946 (international) at least five minutes prior to the start time, and refer to conference ID 4067388. An accompanying presentation will be referenced during the conference call and can be accessed under "Events and Presentations" in the Investors section of OncoSec's website at ir.oncosec.com. A replay will be available shortly after the conference call and can be accessed for 30 days following the call.

About OncoSec Medical Incorporated
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.  OncoSec's lead immunotherapy platform – TAVO™ (tavokinogene telseplasmid) – enables the intratumoral delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions.  The technology, which employs electroporation, is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, enabling the immune system to target and attack tumors throughout the body.  OncoSec has built a deep and diverse clinical pipeline utilizing TAVO™ as a potential treatment for multiple cancer indications either as a monotherapy or in combination with leading checkpoint inhibitors; with the latter potentially enabling OncoSec to address a great unmet medical need in oncology: anti-PD-1 non-responders.  Results from recently completed clinical studies of TAVO™ have demonstrated a local immune response, and subsequently, a systemic effect as either a monotherapy or combination treatment approach.  In addition to TAVO™, OncoSec is identifying and developing new DNA-encoded therapeutic candidates and tumor indications for use with its ImmunoPulse® platform. 

CONTACT
Investor Relations:
Will O'Connor
Stern Investor Relations 
(212) 362-1200
will@sternir.com 

Media Relations:
Michael Lampe
Scient Public Relations, Inc.
(484) 575-5040
michael@scientpr.com 

Editor Details

Related Links

Last Updated: 23-Jan-2019